Trelagliptin Succinate can delay the degradation of endogenous glucagon like peptide-1 (GLP-1), thereby increasing the plasma concentration of active GLP-1.

1、 Drug name

1. Product Name: Zafatek

2. Common name: Trelagliptin Succinate

2、 Indications

It is used for the treatment of type 2 diabetes, as an auxiliary treatment of diet therapy and exercise therapy, when these basic treatment measures are ineffective.

3、 Specifications and characteristics

1. Specification: 100mg

2. Appearance: The tablet surface is printed with dosage markings, and the content is white to off white powder

4、 Main components

1. Active ingredient: Trelagliptin Succinate

2. Additives: including D-mannitol, crystalline cellulose, cross-linked carboxymethyl cellulose sodium, hydroxypropyl cellulose, sodium stearoyl fumarate, hydroxypropyl methylcellulose, polyethylene glycol 6000, titanium oxide, iron oxide and other excipients.

5、 Usage and dosage

The usual dosage for adults is once a week, with each oral dose of 100mg of quercetin (calculated as quercetin).

6、 Dose adjustment

Moderate to severe renal insufficiency patients need to adjust the dosage according to creatinine clearance rate:

1. Moderate renal insufficiency (male Ccr30-50mL/min, female Ccr25-45mL/min): 50mg per week.

2. Severe renal insufficiency or end-stage renal disease (male Ccr<30mL/min, female Ccr<25mL/min): 25mg per week.

7、 Medication precautions

1. Before and after meals: Quegliptin can be taken with food or on an empty stomach, but it is recommended to take it on the same day every week to maintain stable blood drug concentration.

2. Missed dose: If missed, the missed dose should be taken immediately upon discovery, and then taken on the same day every week as originally planned.

3. Vomiting: If continuous vomiting occurs after taking the medication, it is recommended to pause the medication and consult a doctor.

8、 Medication for special populations

1. Pregnant and lactating women: Use only when there is a clear need and the therapeutic benefits outweigh the potential risks.

Animal experiments have shown that quercetin can pass through the placenta and breast milk.

2. Children: No clinical trials have been conducted for children, and safety and efficacy are unknown.

3. Elderly people: Elderly people often have renal dysfunction and should use medication with caution and closely monitor for adverse reactions.

9、 Adverse reactions

Possible adverse reactions include hypoglycemia (increased risk when combined with other hypoglycemic drugs), pemphigus vulgaris, acute pancreatitis, intestinal obstruction, and other serious adverse reactions such as allergic reactions, atrial fibrillation, and elevated liver enzymes.

10、 Contraindications

1. It is forbidden for patients with type 1 diabetes, diabetes ketoacidosis or coma before diabetes.

2. It is contraindicated for patients with severe infections, preoperative and postoperative conditions, and severe trauma.

3. It is contraindicated for individuals allergic to the ingredients of quercetin.

11、 Drug interactions

1. When used in combination with sulfonylureas, fast acting insulin secretagogues, alpha glucosidase inhibitors, biguanide drugs, thiazolidinedione drugs, GLP-1 receptor agonists, and SGLT2 inhibitors, the hypoglycemic effect may be enhanced and the risk of hypoglycemia increased, requiring dosage adjustment.

2. When used in combination with insulin, beta blockers, salicylic acid preparations, monoamine oxidase inhibitors, and drugs for treating fibromuscular hyperlipidemia, it may also affect blood glucose levels and should be monitored carefully.

12、 Storage method

Unopened drugs should be stored at room temperature (below 25 ° C) to avoid moisture and light exposure.

Trelagliptininformation